What was studied?
The randomized trial enrolled 412 people with HIV and abdominal fat accumulation. Investigators followed treatment for 26 weeks and used computed tomography to assess visceral adipose tissue, with additional lipid, hormonal and body-image measurements.
What did the researchers report?
The tesamorelin group showed reduced visceral fat relative to placebo and improvements in some lipid measures. The principal outcome concerned a particular fat compartment, not a general claim about body weight or every form of abdominal adiposity.
What are the limits?
Participants had HIV-associated fat accumulation in the context of their care. The findings should not be transferred to an unselected population or other formulations. Imaging changes are not direct evidence of fewer cardiovascular events or improved long-term survival.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.